Iradimed Co Stock Performance
| IRMD Stock | USD 99.81 0.03 0.03% |
On a scale of 0 to 100, Iradimed holds a performance score of 12. The company retains a Market Volatility (i.e., Beta) of 0.47, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iradimed's returns are expected to increase less than the market. However, during the bear market, the loss of holding Iradimed is expected to be smaller as well. Please check Iradimed's potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Iradimed's current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Iradimed Co are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile primary indicators, Iradimed exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.03) | Five Day Return 4.13 | Year To Date Return 4.51 | Ten Year Return 485.74 | All Time Return 908.18 |
Forward Dividend Yield 0.008 | Payout Ratio | Forward Dividend Rate 0.8 | Dividend Date 2025-12-30 | Ex Dividend Date 2026-02-23 |
1 | Disposition of 1816 shares by Roger Susi of Iradimed at 86.12 subject to Rule 16b-3 | 11/18/2025 |
2 | Disposition of 1000 shares by Hawkins James B of Iradimed at 88.0 subject to Rule 16b-3 | 11/20/2025 |
3 | Disposition of 886 shares by Roger Susi of Iradimed at 91.01 subject to Rule 16b-3 | 11/24/2025 |
| Iradimed dividend paid on 25th of November 2025 | 11/25/2025 |
4 | Disposition of 1197 shares by Allen Monty K of Iradimed subject to Rule 16b-3 | 12/05/2025 |
5 | Disposition of 3000 shares by Hawkins James B of Iradimed at 96.6125 subject to Rule 16b-3 | 12/09/2025 |
6 | Disposition of 731 shares by Roger Susi of Iradimed at 97.13 subject to Rule 16b-3 | 12/15/2025 |
7 | IRADIMED Assessing Valuation After Strong MultiYear Share Price Gains | 12/17/2025 |
| Iradimed dividend paid on 30th of December 2025 | 12/30/2025 |
8 | Disposition of 996 shares by Jeff Chiprin of Iradimed subject to Rule 16b-3 | 01/02/2026 |
9 | Disposition of 112 shares by Roger Susi of Iradimed at 98.15 subject to Rule 16b-3 | 01/12/2026 |
10 | iRadimed Corporation Short Interest Update | 01/20/2026 |
11 | Disposition of 661 shares by Roger Susi of Iradimed at 101.38 subject to Rule 16b-3 | 01/26/2026 |
12 | Ranger Investment Management L.P. Lowers Stake in iRadimed Corporation IRMD | 02/06/2026 |
13 | iRadimed Q4 2025 Earnings Preview | 02/09/2026 |
14 | iRadimed Corporation to Issue Quarterly Dividend of 0.20 | 02/10/2026 |
15 | IRadimed Corporation Q4 2025 Earnings Call Transcript | 02/11/2026 |
16 | Disposition of 1000 shares by Allen Monty K of Iradimed at 100.2563 subject to Rule 16b-3 | 02/13/2026 |
| Begin Period Cash Flow | 49.8 M | |
| Total Cashflows From Investing Activities | -8.8 M |
Iradimed Relative Risk vs. Return Landscape
If you would invest 8,498 in Iradimed Co on November 16, 2025 and sell it today you would earn a total of 1,483 from holding Iradimed Co or generate 17.45% return on investment over 90 days. Iradimed Co is currently generating 0.2803% in daily expected returns and assumes 1.8377% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than Iradimed, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iradimed Target Price Odds to finish over Current Price
The tendency of Iradimed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 99.81 | 90 days | 99.81 | about 21.56 |
Based on a normal probability distribution, the odds of Iradimed to move above the current price in 90 days from now is about 21.56 (This Iradimed Co probability density function shows the probability of Iradimed Stock to fall within a particular range of prices over 90 days) .
Iradimed Price Density |
| Price |
Predictive Modules for Iradimed
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Iradimed. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Iradimed Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Iradimed is not an exception. The market had few large corrections towards the Iradimed's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Iradimed Co, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Iradimed within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.21 | |
β | Beta against Dow Jones | 0.47 | |
σ | Overall volatility | 5.31 | |
Ir | Information ratio | 0.1 |
Iradimed Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Iradimed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Iradimed can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| About 37.0% of the company shares are held by company insiders | |
| On 30th of December 2025 Iradimed paid $ 0.5 per share dividend to its current shareholders | |
| Latest headline from MacroaxisInsider: Disposition of 1000 shares by Allen Monty K of Iradimed at 100.2563 subject to Rule 16b-3 |
Iradimed Fundamentals Growth
Iradimed Stock prices reflect investors' perceptions of the future prospects and financial health of Iradimed, and Iradimed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iradimed Stock performance.
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.31 % | ||||
| Current Valuation | 1.22 B | ||||
| Shares Outstanding | 12.72 M | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 13.40 X | ||||
| Price To Sales | 15.15 X | ||||
| Revenue | 83.81 M | ||||
| Gross Profit | 64.32 M | ||||
| EBITDA | 26.15 M | ||||
| Net Income | 19.23 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 154.69 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 7.43 X | ||||
| Cash Flow From Operations | 25.62 M | ||||
| Earnings Per Share | 1.75 X | ||||
| Market Capitalization | 1.27 B | ||||
| Total Asset | 98.33 M | ||||
| Retained Earnings | 56.79 M | ||||
| Working Capital | 66.73 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
About Iradimed Performance
By analyzing Iradimed's fundamental ratios, stakeholders can gain valuable insights into Iradimed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Iradimed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Iradimed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 202.28 | 164.78 | |
| Return On Tangible Assets | 0.23 | 0.17 | |
| Return On Capital Employed | 0.28 | 0.24 | |
| Return On Assets | 0.22 | 0.17 | |
| Return On Equity | 0.25 | 0.20 |
Things to note about Iradimed performance evaluation
Checking the ongoing alerts about Iradimed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iradimed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 37.0% of the company shares are held by company insiders | |
| On 30th of December 2025 Iradimed paid $ 0.5 per share dividend to its current shareholders | |
| Latest headline from MacroaxisInsider: Disposition of 1000 shares by Allen Monty K of Iradimed at 100.2563 subject to Rule 16b-3 |
- Analyzing Iradimed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iradimed's stock is overvalued or undervalued compared to its peers.
- Examining Iradimed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iradimed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iradimed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iradimed's stock. These opinions can provide insight into Iradimed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |